J. Goldman & CO LP Immunic, Inc. Transaction History

J. Goldman & CO LP

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$3.0 - $5.49 $20,250 - $37,057	-6,750 Reduced 22.25%	23,583 $75,000
Q2 2022 Aug 15, 2022	SELL	$3.13 - $12.25 $222,752 - $871,795	-71,167 Reduced 70.12%	30,333 $105,000
Q1 2022 May 16, 2022	BUY	$9.54 - $14.26 $968,309 - $1.45 Million	101,500 New	101,500 $1.15 Million

55.8M

100

350K

Ticker IMUX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,565,000
Market Cap $28.7M
Description
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and oth...

Get notified when there are updates to the investment portfolio of J. Goldman & CO LP, based on Form 13F filings with the SEC.

Stay updated on J. Goldman & CO LP with notifications on news.